Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance. Cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Cao, Maria, Mayo de las Casas, Clara, Oramas, Juana, Berciano-Guerrero, Miguel A., de la Cruz, Luis, Cerezuela, Pablo, Arance, Ana, Muñoz-Couselo, Eva, Espinosa, Enrique, Puertolas, Teresa, Diaz Beveridge, Roberto, Ochenduszko, Sebastian, Villanueva, Maria-Jose, Basterretxea, Laura, Bellido, Lorena, Rodriguez, Delvys, Campos, Begoña, Montagut, Clara, Drozdowskyj, Ana, Molina, Miguel A., Lopez-Martin, Jose Antonio, Berrocal, Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636498/
https://www.ncbi.nlm.nih.gov/pubmed/34853302
http://dx.doi.org/10.1038/s41467-021-26572-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636498/
https://www.ncbi.nlm.nih.gov/pubmed/34853302
http://dx.doi.org/10.1038/s41467-021-26572-6

Ejemplares similares